Hypoxia stimulates hepatocellular carcinoma (HCC) cell growth via hexokinase (HK) II induction, and alternatively, HK II inhibition induces apoptosis by activating mitochondrial signaling. This study was to investigate whether the induction of HK II by hypoxia is associated with enhanced mitochondrial stability and to confirm the apoptosisinducing efficacy of HK II inhibitor in an in vivo model of HCC. Mitochondrial stability was examined by treating isolated mitochondria with deoxycholate, a permeabilityenhancing agent. Alteration of permeability transition pore complex composition was analyzed by immunoprecipitation and immunoblotting. An in vivo model of HCC was established in C3H mice i.d. implanted with MH134 cells. The antitumor efficacy of i.p. given 3-bromopyruvate (3-BrPA), a HK II inhibitor, was evaluated by measuring tumor volumes and quantifying apoptosis using terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling staining and 99m Tc-hydrazinonicotinamide-Annexin V scans. Hypoxia enhanced mitochondrial stability, and this was inhibited by 3-BrPA treatment. In particular, HK II levels in permeability transition pore complex immunoprecipitates were reduced after 3-BrPA treatment. In mice treated with 3-BrPA, mean tumor volumes and tumor volume growth were found to be significantly reduced. Moreover, percentages of terminal deoxynucleotidyl transferasemediated dUTP nick end labeling -positive cells were significantly increased in 3-BrPA -treated mice, and this apoptosis-inducing efficacy was reflected in vivo by 99m Tc-hydrazinonicotinamide-Annexin V imaging. Our results show that hypoxia enhances mitochondrial stability via HK II induction and that HK II inhibitor treatment exhibits an in vivo antitumor effect by inducing apoptosis. Therefore, HK II inhibitors may be therapeutically useful for the treatment of advanced infiltrative hypovascular HCCs, which are growing in a hypoxic environment. [Mol Cancer Ther 2007;6(9):2554 -62] 
Introduction
Hepatocellular carcinomas (HCC) commonly originate from chronic liver diseases caused by hepatitis virus infections (1 -3) . Therefore, HCC surveillance using regular hepatic ultrasonography and serum a-fetoprotein determinations offer a possible means of detecting small HCCs (4 -6), which are readily treatable using local ablation therapies (7, 8) . Even multinodular or large-sized HCCs, which are not amenable to such local therapies, can be treated by transarterial chemoembolization (9 -11) . However, HCCs sometimes exhibit an infiltrating rather a massforming growth pattern (12) . Moreover, this infiltrating type is not readily detected by regular HCC surveillance in patients with chronic liver diseases and usually presents at an advanced stage (13, 14) .
Advanced HCCs regardless of type are highly malignant and are characterized by their innate resistance to chemotherapeutic agents that are widely and effectively used in other cancer types (15) . Thus, there is an urgent need to develop efficient strategies to treat these cancers. The aggressive growth of advanced infiltrative HCCs may be due to the presence of survival signaling in cancer cells (16) . HCCs are characteristically hypervascular tumors (17, 18) , which suggests that their growths are associated with neovascularization within growing tumor nodules. However, advanced infiltrative HCCs seldom show hypervascularity, although grow more rapidly than massforming types. Therefore, cancer cells in these advanced infiltrative HCCs are likely to generate signals that enable them to survive in hypoxic conditions. Hexokinase (HK), the first enzyme in a glycolytic pathway, is importantly required to maintain cells under hypoxic conditions (19, 20) . Of the four types of HK, HK II is the predominantly overexpressed form in HCCs (21, 22) . Therefore, HK II may participate in cancer cell survival in advanced infiltrative HCCs. Indeed, we recently showed that hypoxia stimulates HCC cell growth via HK II induction and that the inhibition of HK II induces apoptotic cell death by activating mitochondrial apoptotic signaling cascades (23) .
Mitochondrial membrane permeabilization is a major event in the activation of mitochondrial apoptotic signaling (24, 25) , and this permeabilization could be caused by the opening of permeability transition pore complex (PTPC; refs. 26, 27) . HK II binds to the mitochondrial membrane by interacting with the outer membrane protein voltagedependent anion channel (VDAC), which controls the rate of release of mitochondrial intermembrane space proteins that activate the apoptotic process. Thus, HK II binding to VDAC may suppress the release of intermembrane space proteins and inhibit apoptosis and thereby contribute to tumor cell survival (28, 29) .
In the present study, we hypothesized that the induction of HK II by hypoxia is associated with an enhancement in mitochondrial stability and that thus HK II inhibitors would induce apoptosis in an in vivo model of HCC. Collectively, the results of this study show that HK II induction enhances mitochondrial stability and that the inhibition of HK II dissociates this enzyme from PTPC. Moreover, the apoptosis-inducing efficacy of the HK II inhibitor 3-bromopyruvate (3-BrPA) was shown in mice bearing HCCs. Thus, our results suggest that HK II inhibitor may be therapeutically useful for the treatment of advanced HCCs.
Materials and Methods
Chemicals and Reagents 3-BrPA, deoxycholate, trypan blue solution (0.4%), and human Annexin V were purchased from Sigma-Aldrich Chemical Co. Solutions of 3-BrPA were prepared as described previously (30) . Annexin V-FITC and propidium iodide were purchased from BD PharMingen. Sodium [2- 14 C]pyruvate was purchased from Perkin-Elmer Life and Analytical Sciences, Inc.
Cell Culture Huh-BAT cells (Huh-7 cells stably transfected with a bile acid transporter derived from a well-differentiated HCC, a human HCC cell line; refs. 31, 32) were used for in vitro experiments and MH134 cells (a mouse HCC cell line) were used for in vitro and in vivo experiments. Huh-BAT cells were grown in DMEM supplemented with 10% fetal bovine serum, 100,000 units/L penicillin, and 100 mg/L streptomycin, and MH134 cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 100,000 units/L penicillin, and 100 mg/L streptomycin. In all experiments done in this study, cells were serum starved overnight to avoid serum-induced signaling. Depending on the experiment concerned, cells were incubated either under standard culture conditions (20% O 2 and 5% CO 2 , at 37jC) or in hypoxic culture conditions (1% O 2 , 5% CO 2 , and 94% N 2 , at 37jC).
Preparation of Mitochondrial and Cytosolic Extracts Cells were washed twice with PBS, and mitochondrial and cytosolic extracts were isolated using Mitochondria/ Cytosol Fractionation kits (BioVision, Inc.) according to the manufacturer's instructions.
Immunoblot Analysis Cells were lysed for 20 min on ice using lysis buffer [50 mmol/L Tris-HCl (pH 7.4); 1% NP40; 0.25% sodium deoxycholate; 150 mmol/L NaCl; 1 mmol/L EDTA; 1 mmol/L phenylmethylsulfonyl fluoride; 1 Ag/mL aprotinin, leupeptin, and pepstatin; 1 mmol/L Na 3 VO 4 ; 1 mmol/L NaF] and centrifuged at 14,000 Â g for 10 min at 4jC. Samples were resolved by SDS-PAGE, transferred to nitrocellulose membrane, blotted with appropriate primary antibodies, and incubated with peroxidase-conjugated secondary antibodies (Biosource International). Bound antibodies were visualized using a chemiluminescent substrate (enhanced chemiluminescence; Amersham) and exposed to Kodak X-OMAT film. Mouse anti -cytochrome c was obtained from BD PharMingen. Goat anti-AIF, goat anti-HK II, and goat anti-actin were obtained from Santa Cruz Biotechnology, Inc. Mouse anti-Smac/DIABLO was obtained from BD Transduction Laboratories.
Immunoprecipitation Analysis Cell lysates were mixed with 2 Ag of antisera to VDAC (Santa Cruz Biotechnology) and incubated overnight at 4jC. Immune complex was immunoprecipitated with 35 AL of Protein A/G PLUS-Agarose (Santa Cruz Biotechnology) and then washed five times for 10 min with 1 mL of washing buffer. Polypeptides were then resolved by boiling with 35 AL of Laemmli sample buffer for 5 min.
Animals Animal experiments were done with 4-week-old male C3H/He mice (Charles River Laboratories) in accordance with the guidelines established by the Institutional Animal Care and Use Committee of Seoul National University Hospital. Mice were housed under specific pathogen-free conditions. Imaging procedures were carried out under ketamine hydrochloride -induced (80 mg/kg, i.p.) and xylazine hydrochloride -induced (16 mg/kg, i.p.) anesthesia.
Mouse HCC Model
We used an established s.c. HCC mouse model as described previously (33) . Briefly, 2.5 Â 10 5 viable MH134 cells suspended in 0.1 mL of RPMI 1640 were injected i.d. to produce a bleb in the right flanks of C3H mice. When tumor volumes reached 0.2 cm 3 , 3-BrPA was given i.p. for 5 consecutive days. Fourteen days after injecting 3-BrPA, mice were sacrificed by exsanguination via cardiac puncture under general anesthesia (isoflurane inhalation). Tumor masses and liver tissues were then harvested, fixed in 10% formaldehyde, and cryopreserved.
Preparation and Biodistribution of 14 C]BrPA, which is equivalent to 3.31 mg BrPA (average BrPA dose, 141 mg/kg). At selected times after injection (1, 2, 4, and 8 h), mice were sacrificed by exsanguination via cardiac puncture under general anesthesia (isoflurane inhalation). Aliquots of heparinized blood were rapidly centrifuged at 2,000 Â g for 5 min to obtain plasma. Radioactivities of tissues and blood were determined using a h-counter using a liquid scintillation analyzer (Tri-Carb 2300TR, Packard).
Apoptosis Apoptosis in tumor tissue was investigated by terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling (TUNEL) staining using ApopTag Peroxidase In situ Apoptosis Detection kits (Chemicon International) after fixing fresh tissue with 4% paraformaldehyde. Positive TUNEL cells were counted in six different highpower fields at Â400 magnification and averaged. Cell numbers are expressed as percentages of total cells and are referred to as apoptotic indexes.
Cell Viability
Cell viabilities were determined using trypan blue dye exclusion assays. After 4 h of incubation with 3-BrPA, cell pellets were resuspended in PBS. Viable cell numbers were determined by trypan blue staining.
Detection of Apoptosis by Flow Cytometric Analysis Apoptotic or necrotic cell levels were determined by flow cytometry after double staining with Annexin V-FITC and propidium iodide using an assay kit from BD PharMingen as described previously (35 Tc-HYNIC-Annexin V Scan 99m Tc-HYNIC-Annexin V (50 ACi) was injected via a tail vein 1 and 3 days after 3-BrPA treatment. Planar scans were acquired 1 h after injecting 99m Tc-HYNIC-Annexin V using a gamma camera.
Statistical Analysis All data represent at least three independent experiments using cells from a minimum of three separate isolations and are expressed as mean F SD. Statistical evaluations of numerical variables in three 3-BrPA dosage groups were conducted using the Mann-Whitney U test and the KruskalWallis test. Differences in tumor growth were statistically analyzed using repeated measures ANOVA. A scattergram of Annexin V -positive cell fraction and 99m Tc-HYNICAnnexin V uptake was plotted using linear regression analysis (Spearman correlation test). All statistical analyses were done using Statistical Package for the Social Sciences 12.0 for Windows (SPSS, Inc.). P values of <0.05 were considered statistically significant.
Results

Hypoxia Enhances Mitochondrial Stability
Mitochondria were isolated from Huh-BAT cells cultured in normoxic or hypoxic states. Isolated mitochondria were then incubated in the presence of deoxycholate, which is known to enhance mitochondrial membrane permeabilization (38) . Mitochondria isolated from cells cultured in a hypoxic state were more resistant to the permeabilityenhancing effect of deoxycholate than those from cells (Fig. 1A) . Moreover, when isolated mitochondria from hypoxic cells were simultaneously incubated with deoxycholate and 3-BrPA, cytochrome c release occurred at a lower deoxycholate concentration than for mitochondria treated with deoxycholate alone (Fig. 1B) . These findings indicate that hypoxia enhances mitochondrial stability and that the HK II inhibitor 3-BrPA attenuates this enhancement.
Compositional Alterations in PTPC Induced by HK II Inhibitor
Because PTPC regulates mitochondrial stability and HK II is a major component of PTPC, we hypothesized that 3-BrPA may induce the dissociation of HK II from PTPC to open PTPC and thus allow the release of cytochrome c into the cytosol. To test this hypothesis, PTPC was immunoprecipitated using antisera for VDAC from the mitochondrial fractions of Huh-BAT or MH134 cells, which were cultured in the presence of 3-BrPA at 0 to 100 Amol/L. HK II was identified in PTPC immunoprecipitates, as shown in Fig. 2A , and this band intensity diminished in a dose-dependent manner when cells were treated in the presence of 3-BrPA (Fig. 2B) . Thus, these findings suggest that hypoxia enhances mitochondrial stability by inducing HK II association with PTPC and that 3-BrPA dissociates HK II from and thus activates mitochondrial apoptotic signals.
Antitumor Efficacy of 3-BrPA in an In vivo Model of HCC
To evaluate antitumor efficacy of 3-BrPA in an in vivo model of HCC, we established an animal model of HCC in C3H mice by i.d. implanting MH134 cells. We first verified that our mouse model represented a HK II -overexpressing HCC model, and as shown in Fig. 3A , mouse HCC tumors overexpressed HK II versus normal liver tissues.
We next examined the biodistribution and the stability of [ 14 C]BrPA in MH134-bearing C3H mice. As shown in Fig. 3B, [ 14 C]BrPA distributed into all tissues. In particular, its radioactivity profiles in all tissues showed rapid uptake and delayed washout. Overall, highest radioactivity was observed in blood, kidneys, and lungs. In particular, the blood radioactivity of [ 14 C]BrPA was maintained at a high level throughout the 8-h observation period. Tumor-bearing mice were then treated with 3-BrPA (0, 5, and 10 mg/kg, i.p. daily for 5 days). The antitumor efficacy of 3-BrPA was first evaluated by measuring tumor volumes. MH134 cells effectively produced tumors in control mice within 14 days of i.d. injection. However, tumor volumes in 3-BrPA -treated mice were significantly reduced compared with the control mice in a dosedependent manner (mean tumor volume, 1.07 versus 0.58 versus 0.39 cm 3 in 3-BrPA at 0, 5, and 10 mg/kg, respectively; P = 0.047; Fig. 4A ). To control for variations in initial tumor volume in individual mice, we also compared tumor growth rates by dividing differences between posttreatment (day 14) and pretreatment tumor volumes (day 0) by pretreatment volumes. In control mice, tumor volumes increased 4-to 9-fold, whereas this was significantly reduced in 3-BrPA -treated mice (Fig. 4B ). These observations suggest that HK II inhibitor treatment exhibits in vivo antitumor efficacy.
In vivo Demonstration of the Apoptosis-Inducing Efficacy of 3-BrPA
We next evaluated whether 3-BrPA induces apoptosis in mouse HCC tumors. To quantify apoptosis in tumors, we first used TUNEL staining. Percentages of TUNEL-stained cells were significantly higher in 3-BrPA -treated mice (0.53 versus 1.40 versus 1.84% for mice treated with 3-BrPA at 0, 5, and 10 mg/kg, respectively; P = 0.018; Fig. 5A and B) .
We also confirmed the apoptosis-inducing efficacy of 3-BrPA using 99m Tc-HYNIC-Annexin V scans. The validity of the method used was first evaluated in vitro. Briefly, MH134 cells were cultured in the presence of 3-BrPA . Four mice were randomly allocated into each of these 3-BrPA dosage groups. Points, mean tumor volumes; bars, SE. *, P < 0.05 versus control. B, tumor growth rates were calculated by dividing differences between posttreatment (day 14) and pretreatment tumor volumes (TV ; day 0) by pretreatment volumes. Columns, mean values of the three 3-BrPA dosage groups; bars, SD. *, P < 0.05 versus control.
(0 -100 Amol/L), and cell viabilities were measured using trypan blue dye exclusion assays. 3-BrPA (0, 25, 50, and 100 Amol/L) was found to reduce viability in a dosedependent manner (Fig. 6A) . Moreover, these viability reductions were found to be well correlated with apoptotic cell fractions, determined as Annexin V-FITC -positive fractions by flow cytometry (Fig. 6A and B) . Moreover, apoptotic cell fractions were positively correlated with 99m Tc-HYNIC-Annexin V uptake (%ID) in a 3-BrPA dosedependent manner (c 2 = 0.698; P < 0.05; Fig. 6C ). In contrast, a significant decrease in [ 18 F]FDG uptake (%ID) was observed even in cells treated with the lowest concentration of 3-BrPA (25 Amol/L; P < 0.01), and no additional changes in [ 18 F]FDG uptake (%ID) were observed at 3-BrPA concentrations higher than 25 Amol/L (Fig. 6A) . These findings indicate that 99m Tc-HYNICAnnexin V uptake following 3-BrPA treatment sensitively quantifies cellular apoptosis. Indeed, in tumor-bearing mice, 99m Tc-HYNIC-Annexin V imaging showed tumorto-background uptake ratios of 1.92 at 1 day and 4.23 at 3 days after 5 mg/kg of 3-BrPA treatment (nontreated tumors had a mean uptake ratio of 2.93; Fig. 6D ). These findings indicate that 3-BrPA induces apoptosis in an in vivo model of HCC and that this apoptosis-inducing efficacy is reflected in vivo by 99m Tc-HYNIC-Annexin V imaging.
Discussion
The key findings of the present study relate to the participation of HK II in the regulation of mitochondrial stability in HCC cells. In particular, this study shows that hypoxia enhances mitochondrial stability via HK II induction and that HK II inhibition activates mitochondrial apoptotic signals. Moreover, the systemically given HK II inhibitor exhibited antitumor efficacy by inducing apoptosis.
We have previously reported that hypoxia induces HK II expression in HCC cells (23) . In the present study, we also show that hypoxia-mediated HK II induction enhances mitochondrial stability and that 3-BrPA induces structural alteration in PTPC, which leads to the activation of mitochondrial apoptotic signaling. The mechanisms underlying activation of mitochondrial apoptotic signaling are complex and multiple mechanisms result in cytochrome c release. For example, proapoptotic Bcl2 family proteins, such as tBid, Bax/Bak, and Bim, regulate apoptosis by interacting with VDAC in the mitochondrial outer membrane (28, 39, 40) . It is also possible that the opening of mitochondrial permeability transition pores (41) is involved in the outer membrane rupture that allows the release of intermembrane proteins such as cytochrome c, AIF, and Smac/ DIABLO (42, 43) . Although the structure of mitochondrial permeability transition pore has not been completely elucidated, PTPC is a complex composed of a variety of proteins, which include VDAC, ANT, CypD, and HK II (44 -47) . The present study shows that the HK II inhibitor 3-BrPA causes the dissociation of HK II from PTPC and that this causes PTPC opening and the release of cytochrome c into the cytosol. Therefore, these observations collectively suggest that HK II induction is one of the major mechanisms of cell survival in hypoxic environments, such as that in advanced infiltrative hypovascular HCCs, and that HK II inhibitors may exhibit antitumor efficacy by activating mitochondrial apoptotic signals in these advanced tumors.
We also evaluated the in vivo antitumor efficacy of 3-BrPA. Several in vivo studies using rat AS-30D or rabbit VX2 HCC models have shown the antitumor efficacy of 3-BrPA (30, 48) . However, these studies evaluated the efficacy of locally injected 3-BrPA via selective intraarterial or intratumoral injection, whereas the present study shows the antitumor efficacy of i.p. given 3-BrPA. I.p. administration is a means of systemic delivery, as it allows peritoneal absorption and subsequent portal delivery, which mimics the effects of oral administration. Moreover, we also evaluated the antitumor efficacy of 3-BrPA in vivo by quantifying apoptosis and measuring tumor volumes. As shown by our TUNEL staining findings, apoptotic cells were significantly more abundant in 3-BrPA -treated mice than in nontreated controls. However, the TUNEL staining method used is only applicable in retrieved tumor tissues, and therefore, we also attempted to evaluate the apoptosis-inducing efficacy Tc-HYNIC-Annexin V (50 ACi/2 Ag/0.1 mL/head) was injected into a tail vein. Gamma camera images were obtained 1 h later. T, tumor (MH134 tumor).
of systemically given 3-BrPA using 99m Tc-labeled Annexin V in vivo imaging (49) . The validity of this imaging modality was confirmed by our in vitro experiments, which showed 99m Tc-HYNIC-Annexin V uptake in apoptotic mouse HCC cells. Moreover, this imaging modality was also able to dynamically quantify cellular apoptosis following 3-BrPA injection even before tumor regression. In contrast, [ 18 F]FDG scans were unsuitable for monitoring the in vivo antitumor efficacy of 3-BrPA because HK II inhibitor suppressed [ 18 F]FDG uptake as well as glucose uptake in cells treated with even the lowest concentration of 3-BrPA (25 Amol/L). Therefore, these findings collectively indicate that systemically given 3-BrPA may exhibit antitumor efficacy by inducing cellular apoptosis and that this may be quantifiable by 99m Tc-labeled Annexin V in vivo imaging.
Human HCC cells overexpress HK II, as we showed previously (23) . Moreover, in the present study, we also observed HK II overexpression in tumor tissues compared with normal liver tissues (Fig. 3A) , and thus, 3-BrPA uptake by normal liver tissues is expected to be negligible. Indeed, the distribution of [
14 C]BrPA in liver was low in the present study. Moreover, no adverse effect or toxicity was found following 3-BrPA administration, and no significant difference in mean body weights was observed among mice treated with different doses of 3-BrPA or between these and control mice (data not shown). In addition, in liver tissue blocks obtained from 3-BrPA -treated mice, no pathologic features or increases in hepatocyte apoptotic indices were observed versus control mice (data not shown). Therefore, these findings collectively suggest that 3-BrPA treatment might be a selective anticancer therapy because its uptake in HCC cells is maximized by high HK II expression levels, whereas its uptake by surrounding normal liver tissue is minimized.
In conclusion, the present study shows that hypoxia enhances mitochondrial stability via HK II induction and that the inhibition of HK II causes release of this enzyme from PTPC, thus leading to the activation of mitochondrial apoptotic signals. Moreover, the apoptosis-inducing efficacy of HK II inhibitor was shown in animals bearing HCCs. Therefore, we conclude that blockage of HK II may be therapeutically useful for the management of advanced infiltrative hypovascular HCCs, which are aggressively growing in a relatively hypoxic environment.
